Table 2.

Immunological risk assessment strategy: current approach of the Munich Lung Transplant Group (MLTP)

Risk group	I low risk	II risk	III high risk	IV very high risk
HLA alloimmunization	–	+	+	+
CDC ab	–	–	–	+
Luminex ab (PRA)	–	<50%	>50%	>85%
Unacceptable antigen	–	+	+	+
Risk HLA	–	–	+	+
Crossmatch	–	Virtual	Virtual	CDC

ab, antibodies; PRA, panel-reactive antibodies; CDC, complement-dependent cytotoxicity.